22 studies found for:    stx209
Hide Display Options

Display Options

Study Details
Participant Details
Identifiers
Dates
Rank Status Study
1 Recruiting MEG Study of STX209
Condition: Autism Disorder
Interventions: Drug: STX209;   Drug: placebo
2 Terminated Open Label Extension Study of STX209 (Arbaclofen) in Autism Spectrum Disorders
Condition: Autism Spectrum Disorders
Intervention: Drug: STX209 (arbaclofen)
3 Completed Efficacy and Safety Study of STX209 (Arbaclofen) for the Treatment of Social Withdrawal in Children With Fragile X Syndrome
Condition: Fragile X Syndrome
Interventions: Drug: arbaclofen;   Drug: Placebo
4 Completed
Has Results
Safety, Tolerability and Efficacy Study of STX209 in Subjects With Fragile X Syndrome
Condition: Fragile X Syndrome
Interventions: Drug: STX209;   Drug: Placebo
5 Terminated An Open Label Extension Study of STX209 in Subjects With Autism Spectrum Disorders
Condition: Autism Spectrum Disorders
Intervention: Drug: arbaclofen
6 Terminated An Open Label Extension Study of STX209 in Subjects With Fragile X Syndrome
Condition: Fragile X Syndrome
Intervention: Drug: Arbaclofen
7 Completed
Has Results
Open-Label Study of the Safety and Tolerability of STX209 in Subjects With Autism Spectrum Disorders
Condition: Autism Spectrum Disorders
Intervention: Drug: Arbaclofen
8 Completed Efficacy and Safety Study of STX209 (Arbaclofen) for Social Withdrawal in Adolescents and Adults With Fragile X Syndrome
Condition: Fragile X Syndrome
Interventions: Drug: arbaclofen;   Drug: placebo
9 Completed A Study to Evaluate the Efficacy and Safety of Arbaclofen Placarbil (XP19986) as Adjunctive Therapy in Subjects With Gastroesophageal Reflux Disease (GERD)
Condition: Gastroesophageal Reflux Disease
Interventions: Drug: arbaclofen placarbil-Cohort 1;   Drug: Placebo-Cohort 5;   Drug: arbaclofen placarbil-Cohort 2;   Drug: arbaclofen placarbil-Cohort 3;   Drug: arbaclofen placarbil-Cohort 4;   Drug: PPI
10 Active, not recruiting One Year, Open Label, Dose Escalation Long-term Safety Study in Multiple Sclerosis (MS) Subjects With Spasticity
Conditions: Multiple Sclerosis;   Spasticity
Intervention: Drug: arbaclofen
11 Completed Study of Arbaclofen for the Treatment of Social Withdrawal in Subjects With Autism Spectrum Disorders
Condition: Autism Spectrum Disorders
Intervention: Drug: Arbaclofen
12 Completed Efficacy Study of Arbaclofen to Treat Spasticity in Multiple Sclerosis
Conditions: Spasticity;   Multiple Sclerosis
Interventions: Drug: arbaclofen;   Drug: baclofen;   Drug: Placebo
13 Completed Efficacy and Safety of Arbaclofen Placarbil in Subjects With Spasticity Due to Multiple Sclerosis
Condition: Multiple Sclerosis
Interventions: Drug: arbaclofen placarbil;   Drug: Placebo
14 Completed Arbaclofen Placarbil for the Treatment of Spasticity in Subjects With Multiple Sclerosis (MS)
Condition: Multiple Sclerosis
Intervention: Drug: arbaclofen placarbil
15 Completed Biomarker Testing and DNA Collection in Subjects Participating in Protocol 22001
Condition: Fragile X Syndrome
Intervention: Drug: STX209
16 Completed A Study to Evaluate the Safety and Tolerability of Arbaclofen Placarbil (XP19986) in Subjects With Acute Back Spasms
Condition: Back Spasms
Interventions: Drug: Arbaclofen placarbil, 20 mg BID;   Drug: Placebo;   Drug: Arbaclofen placarbil, 30 mg BID;   Drug: Arbaclofen placarbil, 40 mg BID
17 Completed Biomarker and DNA Collection in Subjects Participating in Protocol 22003
Condition: Fragile X Syndrome
Intervention: Drug: STX209
18 Terminated An Open Label Extension Study in Subjects With Fragile X Syndrome
Condition: Fragile X Syndrome
Intervention: Drug: arbaclofen
19 Completed A Study to Evaluate the Efficacy and Safety of Controlled Release Arbaclofen Placarbil (XP19986) in Patients With Gastroesophageal Reflux Disease
Condition: GERD
Intervention: Drug: arbaclofen placarbil
20 Terminated TMS Measures of Plasticity and Excitatory/Inhibitory Ratio as Biomarkers: R-baclofen Effects in Normal Volunteers
Condition: Autism
Intervention: Drug: R-baclofen

   Previous Page Studies Shown (1-20) Next Page (21-22) Show next page of results    Last Page
Indicates status has not been verified in more than two years